All In MedTech

FDA Clearance Tracker · P160048-S022

Eversense® E3 Continuous Glucose Monitoring (CGM) System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Mar 30, 2023 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Mar 30, 2023

Approved

Time to decision

58 days

Received Jan 31, 2023. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P160048-S022
Device name
Eversense® E3 Continuous Glucose Monitoring (CGM) System
Applicant location
Germantown, MD
Received
Jan 31, 2023
Decided
Mar 30, 2023
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P160048

Device type

Device class
Class III

Every decision under product code QHJ

FDA's approval statement

As written in FDA's record.

Approval for modifying the Eversense E3 Transmitter, supporting mobile medical application, and the Instructions for Use for consistent use with the modified transmitter.

Source documents

Other decisions for Senseonics, Incorporated

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.